BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND PALB2, ENSG00000083093, 79728 AND Diagnosis
56 results:

  • 1. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
    Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
    J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
    Kahn RM; Selenica P; Boerner T; Roche KL; Xiao Y; Sia TY; Maio A; Kemel Y; Sheehan M; Salo-Mullen E; Breen KE; Zhou Q; Iasonos A; Grisham RN; O'Cearbhaill RE; Chi DS; Berger MF; Kundra R; Schultz N; Ellenson LH; Stadler ZK; Offit K; Mandelker D; Aghajanian C; Zamarin D; Sabbatini P; Weigelt B; Liu YL
    Gynecol Oncol; 2024 Jan; 180():35-43. PubMed ID: 38041901
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Association of Glycated Hemoglobin With a Risk of Pancreatic cancer in High-Risk Individuals Based on Genetic and Family History.
    Wu BU; Chen Q; Moon BH; Lustigova E; Nielsen EG; Alvarado M; Ahmed SA
    Clin Transl Gastroenterol; 2024 Jan; 15(1):e00650. PubMed ID: 37800692
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Germline Mutations in 12 Genes and Risk of Ovarian cancer in Three Population-Based Cohorts.
    Kotsopoulos J; Hathaway CA; Narod SA; Teras LR; Patel AV; Hu C; Yadav S; Couch FJ; Tworoger SS
    Cancer Epidemiol Biomarkers Prev; 2023 Oct; 32(10):1402-1410. PubMed ID: 37493628
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes.
    Møller NB; Boonen DS; Feldner ES; Hao Q; Larsen M; Lænkholm AV; Borg Å; Kvist A; Törngren T; Jensen UB; Boonen SE; Thomassen M; Terkelsen T
    Sci Rep; 2023 May; 13(1):8536. PubMed ID: 37237042
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. palb2 germline mutations in a large cohort of Middle Eastern breast-ovarian cancer patients.
    Siraj AK; Bu R; Parvathareddy SK; Iqbal K; Azam S; Qadri Z; Al-Rasheed M; Haqawi W; Diaz M; Victoria IG; Al-Badawi IA; Tulbah A; Al-Dayel F; Ajarim D; Al-Kuraya KS
    Sci Rep; 2023 May; 13(1):7666. PubMed ID: 37169825
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Adherence to NCCN Genetic Testing Guidelines in Pancreatic cancer and Impact on Treatment.
    Crowley F; Gandhi S; Rudshteyn M; Sehmbhi M; Cohen DJ
    Oncologist; 2023 Jun; 28(6):486-493. PubMed ID: 36933202
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.
    Bychkovsky BL; Lo MT; Yussuf A; Horton C; Hemyari P; LaDuca H; Garber JE; Scheib R; Rana HQ
    Breast Cancer Res Treat; 2023 Jul; 200(1):63-72. PubMed ID: 36856935
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
    Chapin WJ; Reiss KA
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22).
    Musacchio L; Califano D; Bartoletti M; Arenare L; Lorusso D; Losito NS; Cormio G; Greggi S; Raspagliesi F; Valabrega G; Salutari V; Pisano C; Spina A; Russo D; Del Sesto M; Canzonieri V; Ferraù F; Zannoni GF; Loizzi V; Ghizzoni V; Casanova C; Tuninetti V; Ducceschi M; Del Vecchio V; Scalone S; Priolo D; Perrone F; Scambia G; Pignata S
    Br J Cancer; 2022 Nov; 127(8):1479-1486. PubMed ID: 35869143
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a diagnosis of Epithelial Tubo-Ovarian Carcinoma.
    Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
    J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer.
    Kotsopoulos J; Zamani N; Rosen B; McLaughlin JR; Risch HA; Kim SJ; Sun P; Akbari MR; Narod SA
    Br J Cancer; 2022 Sep; 127(5):879-885. PubMed ID: 35710751
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. palb2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
    Gonzalez A; Del Greco F; Vargas-Roig L; Brun B; Tabares G; Mampel A; Montes C; Martin C; Lopez M; Rossi N; Bruno L; Ponce C; Quaglio P; Yanzi A; Acevedo S; Lugo L; Lopez Breccia P; Avila S; Sisterna S; Del Castillo MS; Vazquez M; Nuñez LM
    Breast Cancer Res Treat; 2022 Jul; 194(2):403-412. PubMed ID: 35610400
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
    Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
    Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Pancreatic Ductal Carcinoma Risk Associated With Hereditary cancer-Risk Genes.
    Gardiner A; Kidd J; Elias MC; Young K; Mabey B; Taherian N; Cummings S; Malafa M; Rosenthal E; Permuth JB
    J Natl Cancer Inst; 2022 Jul; 114(7):996-1002. PubMed ID: 35445726
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Detection of a pathogenic Alu element insertion in palb2 gene from targeted NGS diagnostic data.
    Eyries M; Ariste O; Legrand G; Basset N; Guillerm E; Perrier A; Duros C; Cohen-Haguenauer O; de la Grange P; Coulet F
    Eur J Hum Genet; 2022 Oct; 30(10):1187-1190. PubMed ID: 35277653
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Hereditary pancreatic cancer.
    Abe K; Kitago M; Kitagawa Y; Hirasawa A
    Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Clinical Contribution of Next-Generation Sequencing Multigene Panel Testing for BRCA Negative High-Risk Patients With Breast cancer.
    Ece Solmaz A; Yeniay L; Gökmen E; Zekioğlu O; Haydaroğlu A; Bilgen I; Özkınay F; Onay H
    Clin Breast Cancer; 2021 Dec; 21(6):e647-e653. PubMed ID: 33980423
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian cancer in the Caribbean.
    George SHL; Donenberg T; Alexis C; DeGennaro V; Dyer H; Yin S; Ali J; Butler R; Chin SN; Curling D; Lowe D; Lunn J; Turnquest T; Wharfe G; Cerbon D; Barreto-Coelho P; Schlumbrecht MP; Akbari MR; Narod SA; Hurley JE
    JAMA Netw Open; 2021 Mar; 4(3):e210307. PubMed ID: 33646313
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.